Impaired coronary microvascular endothelial function in men with metabolic syndrome

Table 2 Patients’ characteristics regarding other risk factors and medications (mean ± SE) n (%)

Variables	MS group	Non-MS group	P value
Other risk factors
Smoking	13 (54)	16 (35)	NS
Hypercholesterolemia1	6 (25)	10 (18)	NS
Total cholesterol (mg/dL)	206 ± 7	194 ± 5	NS
Triglyceride (mg/dL)	205 ± 17	157 ± 11	0.0218
HDL cholesterol (mg/dL)	44 ± 3	52 ± 2	0.0204
LDL cholesterol (mg/dL)	121 ± 6	111 ± 4	NS
Diabetes mellitus	5 (21)	5 (9)	0.0189
Fasting blood sugar (mg/dL)	107 ± 3	98 ± 2	0.0189
Hemoglobin A1C	5.7 ± 0.1	5.4 ± 0.1	0.0445
HOMA-IR	2.5 ± 0.2	1.7 ± 0.1	0.0046
C-reactive protein (mgl/L)	1.7 ± 0.3	1.3 ± 0.2	NS
Medications
Statins	1 (4)	6 (11)	NS
ACI or ARB	2 (8)	1 (2)	NS

¹On therapy and/or low-density lipoprotein (LDL)-cholesterol ≥ 140 mg/dL. MS: Metabolic syndrome; NS: Not significant; HDL: High-density lipoprotein; HOMA-IR: Homeostasis of assessment-insulin resistance; ACI: Angiotensin-converting enzyme inhibitor; ARB: Angiotensin receptor blocker.